

FORM PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER TSRI 663.1	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	
				09/762376 ✓	
INTERNATIONAL APPLICATION NO. PCT/US99/18154 ✓		INTERNATIONAL FILING DATE 10 August 1999 ✓		PRIORITY DATE CLAIMED 10 August 1998 ✓	
TITLE OF INVENTION alpha2,8/2,9 POLYSIALYLTRANSFERASE ✓					
APPLICANT(S) FOR DO/EO/US Wong, et al. <i>WONG CHI-LUKY</i>					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input type="checkbox"/> is attached hereto.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <i>unsigned</i></p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p><b>Items 11 to 20 below concern document(s) or information included:</b></p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: <i>Certificate of Express Mailing; Return Receipt Postcard</i></p>					

U.S. APPLICATION NO. (if known, see 37 CFR 1.51)

09/762376

INTERNATIONAL APPLICATION NO  
PCT/US99/18154

ATTORNEY'S DOCKET NUMBER

TSRI 663.1

21. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO. .... \$1000.00

International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO  
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

CALCULATIONS PTO USE ONLY

\$ 690.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	8 - 20 =	0	x \$18.00	\$
Independent claims	5 - 3 =	2	x \$80.00	\$ 160.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$

**TOTAL OF ABOVE CALCULATIONS =**

\$ 850.00

☒ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above  
are reduced by 1/2. +

\$ 425.00

**SUBTOTAL =**

\$

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

**TOTAL NATIONAL FEE =**

\$ 425.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$

**TOTAL FEES ENCLOSED =**

\$ 425.00

Amount to be  
refunded:

\$

charged:

\$

- a. ☒ A check in the amount of \$ 425.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 19-0962. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card  
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR  
1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

THE SCRIPPS RESEARCH INSTITUTE  
Office of Patent Counsel  
10550 North Torrey Pines Road, TPC-8  
La Jolla, California 92037  
(858) 784-2937

SIGNATURE



NAME

Donald G. Lewis

NAME

28,636

REGISTRATION NUMBER

09/762376

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
DESIGNATED/ELECTED OFFICE (DO/EO/US)

CERTIFICATION UNDER 37 CFR §1.10

I hereby certify that this RESPONSE and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service Express Mail Label No. **EL587948871US** under 37 CFR §1.10, on the date indicated below and is addressed to: Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

Nancy Barker  
Nancy Barker

10/9/01  
Date of Deposit

Applicant: Wong, et al. )  
)  
U.S. Serial No.: 09/762,376 )  
) Art Unit No.: Unassigned  
)  
International )  
Application No.: PCT/US99/18154 ) Examiner: Unassigned  
)  
International )  
Filing Date: August 10, 1999 )  
) Our Ref. No.: TSRI 663.1  
Title:  $\alpha$ 2,8/2,9 POLYSIALYLTRANSFERASE )  
)  
)

**RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS**  
**UNDER 35 U.S.C. 371 IN THE UNITED STATES**  
**DESIGNATED/ELECTED OFFICE (DO/EO/US)**

Assistant Commissioner for Patents  
Washington, D.C. 20231  
ATTN: BOX PCT

Dear Sir:

In response to the enclosed copy of the PTO Communication regarding the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed August 10, 2001, enclosed is a Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. Also enclosed is the Sequence Listing in computer readable form, submitted as required by 37 CFR §1.821(e), on which the Sequence Listing is labeled

09/762376 09/762376

663.1/OPT 0022P.

Applicants respectfully request entry of the Sequence Listing and computer readable copy thereof.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR \$1.821(a) through (c) and (e), respectively, are the same and include no new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

By   
Donald G. Lewis, Reg. No. 28,636

THE SCRIPPS RESEARCH INSTITUTE  
10550 North Torrey Pines Road  
Mail Drop TPC-8  
La Jolla, California 92037  
(858) 784-2937

$\alpha$ 2,8/2,9 POLYSIALYLTRANSFERASEDescriptionTechnical Field:

5 The invention relates to  $\alpha$ 2,8/2,9 polysialyltransferase and to methods for producing and using recombinant  $\alpha$ 2,8/2,9 polysialyltransferase.

Background:

10 The 9-carbon 5-amino-3,5-dideoxy-D-glycero-D-galacto-nonulosonic acids or sialic acids, comprise a family of neuraminic acid derivatives which are widely spread in nature, ranging from bacterial to human origin. This sugar moiety linked to carbohydrate chains of glycolipids and glycoproteins plays a key role in many important biological events mediated by carbohydrate-protein interactions (Schauer, R. et al. (1995) *Biology of the Sialic acids*, pp 7-67, Plenum Press, New York., Rosenberg, A. ed). Sialic acids are also found in linear homopolymers (polySia) of *N*-acetylneuraminic acid (Neu5Ac) and *N*-glycolylneuraminic acid (Neu5Gc) joined by  $\alpha$ 2,8-,  $\alpha$ 2,9- or  $\alpha$ 2,8/ $\alpha$ 2,9-ketosidic linkages (Troy, F.A. (1992) *Glycobiology* 2, 5-23). The degree of polymerization can extend beyond 200 sialic acid residues (Rohr, T.E. et al. (1980) *J. Biol. Chem.*, **255**, 2332-2342.), thereby constituting a structurally unique group of carbohydrate polymers which covalently modify cell-surface glycoconjugates (Troy, 15 F.A. (1990) *Trends Glycosci. Glycotechnol.* 2, 430-449). Polysialylation of the mammalian neural cell adhesion molecules (NCAM), for example, affects the cell-cell adhesive interactions during embryogenesis, including neurite fasciculation and neuromuscular interactions (Edelman, G. M.. (1985) *Cold Spring Harbor Symp. Quant. Biol.* **50**: 877-889; and Cunningham, B. A. et al. (1987) *Science* **236**: 799-806). While 20 the neuroinvasive bacteria *Escherichia coli* K1 contain a homopolymer of (-8-NeuAc $\alpha$ 2-) (Troy, F. A. et al. (1979) *J. Biol. Chem.* **254**, 7377-7387), the *Neisseria meningitidis* Group C (Liu, T.-Y. et al. (1971) *J. Biol. Chem.* **246**: 4703-4712; and 25

Vann, W. F. et al. (1978) *J. Bacteriol.* **133**, 1300-1306) displays a homopolymer of (-9-NeuAc $\alpha$ 2-) linkages. On the other hand, the polySia capsular antigens of neuroinvasive *E. coli* K92 are composed of poly (-8NeuAc $\alpha$ 2,9NeuAc $\alpha$ 2-) residues (Egan, W. et al. (1977) *Biochemistry*, **16**, 3687-3692). Alternating linkages of

5  $\alpha$ 2,8NeuAc- and  $\alpha$ 2,9NeuAc- could not be found in mammalian systems, and therefore could be utilized to elicit immunological response. In fact, the heteropolymer from the K92 strain of *E. coli* is being employed as a carbohydrate vaccine in the clinical trial of patients suffering from acute meningitis (Devi, S. J. et al. (1991) *Proc Natl Acad Sci U S A*, **88**, 7175-9).

10 The sialyltransferases that catalyze the addition of sialic acid to form such diverse carbohydrate recognition molecules fall into at least two families. While 13 clones have been obtained from mammalian systems (Tsuji, S. et al. (1996) *Glycobiology* **6**, v-vii), only 4 have been cloned from bacterial systems to date (Vimr, E. R. et al. (1992) *J. Bacteriol* **174**, 5127-5131; Gilbert, M. et al. (1997) *Eur. J. Biochem.* **249**: 187-194; and Yamamoto T. et al. (1998) *J. Biochem* (Tokyo) **123**, 94-100). Recent cloning of both mammalian and bacterial sialyltransferases showed that these two gene families evolved differently. The polysialyltransferase (polyST) encoded by *neuS* in *E. coli* uses CMP-sialic acid as a donor and catalyzes a sequential

15 addition of sialic acid to the nonreducing end of an acceptor (Kundig, F. D. et al. (1971) *J. Biol Chem.* **246**: 2543-2550; and Steenbergen, S.M. et al. (1990) *Molecular Microbiology* **4**: 603-611). In a detailed study using the pathogenic strain of *E. coli* K1, the gene coding for CMP-Neu5Ac: poly- $\alpha$ 2,8 sialosyl sialyltransferase, termed *neuS*, has been cloned. This gene was found to be clustered in the *kps* region which is

20 implicated in the initiation, polymerization and possibly translocation of polySia chains across the inner membrane (Weisgerber, C. et al. (1991) *Glycobiology* **1**, 357-365; Weisgerber, C. et al. (1990) *J. Biol. Chem.* **265**, 1578-1587; and Steenbergen, S.M. et al. (1991) *Glycoconjugate J.* **8**, 145). A similar gene has been identified by hybridization to the K92 strain of *E. coli*, the capsule of which contains poly

25 (-8NeuAc $\alpha$ 2,9NeuAc $\alpha$ 2-) (ibid, Egan, W. et al. 1977) . The complete nucleotide

30

- 3 -

sequence of this K92 *neuS* gene showed that this gene product differs by 70 amino acids from the K1 *neuS* gene product (ibid, Vimr, E.R. 1992). Though an *in vitro* study indicated that the *neuS* from *E.coli* K1 coding for a 47 kd protein has polysialyltransferase activity, no such activity has yet been clearly demonstrated for the *neuS* product from *E. coli* K92.

#### Summary:

Disclosed herein is the cloning of the *neuS* gene from the K92 strain of *E.coli* by PCR using the primers described previously (ibid, Vimr, E. R. et al. 1992), expressed the gene in *E.coli*, and shown that the enzyme from this gene catalyzes the synthesis of polysialic acids with both  $\alpha 2,8$  and  $\alpha 2,9$ -linkages *in vitro* and *in vivo*.

One aspect of the invention is directed to DNA plasmid (ATCC \_\_\_\_\_) designated as BL21/DE3(8,9 PST) containing the *neuS* gene from *escherichia coli* K92 and encoding  $\alpha 2,8/2,9$  polysialyltransferase from *escherichia coli* K92.

Another aspect of the invention is directed to a transformed cell having a gene encoding  $\alpha 2,8/2,9$  polysialyltransferase from *escherichia coli* K92.

Another aspect of the invention is directed to a process for obtaining purified  $\alpha 2,8/2,9$  polysialyltransferase. In the first step of the process, a transformed cell having a gene for  $\alpha 2,8/2,9$  polysialyltransferase expresses such gene. The expressed  $\alpha 2,8/2,9$  polysialyltransferase is then purified. In a preferred mode, the  $\alpha 2,8/2,9$  polysialyltransferase is from *escherichia coli* K92.

Another aspect of the invention is directed to purified recombinant  $\alpha 2,8/2,9$  polysialyltransferase. In a preferred embodiment, the  $\alpha 2,8/2,9$  polysialyltransferase is from *escherichia coli* K92.

- 4 -

Another aspect of the invention is directed to a process for converting a substrate of  $\alpha 2,8/2,9$  polysialyltransferase into a product. In this process, the substrate is contacted with  $\alpha 2,8/2,9$  polysialyltransferase under conditions for promoting enzymic catalysis of a conversion of the substrate into the product. In a preferred mode, the  $\alpha 2,8/2,9$  polysialyltransferase is from *escherichia coli* K92.

#### Brief Description of the Figures:

Figure 1 illustrates the construction of the expression vector for the K92 neuS expression as a fusion protein. The PCR fragment 91.2 kb obtained for the full-length form of the K92 *neuS* gene using its genomic DNA as template, was subcloned in pRSET vector (Novagen, Madison, WI) by using two unique restriction sites *Bam* HI and *Eco* RI. This resulted in the expression of the protein with a hexameric histidine tag fused at its *N*-terminal end. The vector provides the start codon followed by the sequence for the hexameric histidine. The full length form of the protein remains mostly as membrane bound form. However, about 30-40% of the protein is "released" in the 40K Sup upon treatment with a detergent. This released protein retains full catalytic activity and was used in this study.

Figure 2 illustrates a hydrophilicity plot and the predicted secondary structure for the  $\alpha 2,8/2,9$  polysialyltransferase. The hydrophilicity plot of the full length form of the K92 neuS gene product suggests the presence of two predicted membrane retention signals in the middle of the polypeptide. The occurrence of this protein (both native and recombinant full-length form) as membrane bound form also supports this model. It is disclosed that approximately 30-40% of the protein is "released" in the 40K Sup using suitable detergent. This released protein retains full catalytic activity and was used in this study. The hydrophilicity plot was compared with that of mammalian ST6Gal I (Weinstein et al 1987) as a representative. This enzyme is predicted to contain only one membrane spanning domain.



- 5 -

Figure 3 illustrates a Western blot analysis of the K92 neuS expressed protein. *E.coli* cells of BL21(DE3) transformed with K92 *neuS* gene in the expression vector pRSET were induced with IPTG (1 mM final concentration) and harvested after 4 hrs. Cells transformed with pRSET vector only were also grown and used as negative control. As a positive control, BL21(DE3) previously transformed with the histidine tagged thioesterase gene (40) subcloned in pET20B(+) were grown, induced, and harvested similarly. After harvesting, the cells were lysed and the supernatants were collected after centrifugation at 15,000 rpm (15K Sup). The proteins were run using a 12% SDS-PAGE as mentioned in the 'Materials and Methods'. The samples were: 15K Sup from the negative control (lane 1), 15K Sup from the cells transformed with K92 *neuS* gene (lane 2), and 15K Sup from the positive control (lane 3). The blot was developed using anti-(His)<sub>6</sub> antibody (Qiagen) and metal enhanced DAB substrate kit (Pierce). The neuS expressed  $\alpha$ 2,8/2,9-polysialyltransferase migrated in the gel at about 47.5 kd. In lane 3, the positive control for the Western blot showed a band at ~ 23 kd for the thioesterase. It may be noted that the expression level for the *neuS* gene was comparatively lower than the thioesterase gene.

Figure 4 illustrates an analysis of the enzyme reaction products by thin-layer chromatography (TLC). The 40K Sup was used as a source of the enzyme in the reaction mixture containing 1 mM acceptor and CMP[<sup>14</sup>C]NeuAc (9 nmol; 1.(Ci) as donor in a reaction buffer containing 25 mM Tris-HCl (pH 8.0), 5 mM MgCl<sub>2</sub>, 5 mM DTT, and 0.5% Triton CF-54. As an example, analysis was shown with the reaction mixture containing sialic acid and GM<sub>3</sub> as acceptors and CMP[<sup>14</sup>C]NeuAc as donor substrate. As a negative control, the reaction mixture contained sialic acid as acceptor without the addition of any enzyme. For A and B, silica gel 60 TLC plates were used for the samples: reaction mixture without the enzyme (lane 1), GM<sub>3</sub> as acceptor (lane 2), sialic acid as acceptor (lane 3), and reaction mixture without exogenous sialic acid (lane 4). The solvents used were: (A) *n*-propanol:1 M NH<sub>4</sub>OH: water:: 7 : 1 : 2; (B) chloroform : methanol: 0.02%CaCl<sub>2</sub>:: 45: 55: 10. The reaction mixtures were also analyzed by DEAE-cellulose TLC. After the reaction was complete, a part of the

- 6 -

sample was acidified with 10% acetic acid and incubated for 30 min at room temperature. For C, DEAE-cellulose TLC plate was used. The samples were: reaction mixture with sialic acid as acceptor (lane 1) and after acidification (lane 2); reaction mixture without enzyme (lane 3) and after acidification (lane 4); using GM<sub>3</sub> as acceptor (lane 5) and after acidification (lane 6); reaction mixture without exogenous acceptor (lane 7) and after acidification (lane 8). The solvents in C used were: *n*-propanol: 14.5 M NH<sub>4</sub>OH: water:: 6: 1: 3. The plates were dried after the run and exposed to a Kodak<sup>®</sup> XAR-5 film. The arrow mark indicates the position of the potential cell free reaction product(s). The position of CMP-NeuAc and free sialic acid were also shown. We found that both the enzyme and its reaction products are unstable and degrade over time.

Figure 5 illustrates the structure of the cell-free reaction product. The product obtained by the cell-free reaction using K92 *neuS* protein, indicated the structure of a pentameric sialic acid with alternating  $\alpha$ 2,9/2,8-linkages (I). The proposed major lactone form (II) obtained in the enzymatic reaction is also shown.

#### Detailed Description:

The abbreviations used herein are: NeuAc, neuraminic acid; PCR, polymerase chain reaction; CMP-NeuAc, CMP-neuraminic acid or CMP-sialic acid; nt., nucleotide(s); TLC, thin layer chromatography.

#### *Cloning of K92 neuS gene:*

The genomic DNA isolated from *Escherichia coli* strain K92 (ATCC 35860) using a DNA extraction kit (Qiagen Co., Valencia, CA) was used for the amplification of *neuS* gene by PCR. This was performed in a 100  $\mu$ l reaction mixture containing 100 ng of genomic DNA as template, 300 nmoles of primers, 200 mM of dNTPs, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 2 mM MgCl<sub>2</sub>, 0.01% gelatin, 0.1% Triton X-100 and a mixture of both *Taq* DNA polymerase and *pfu* DNA polymerase (1 unit of each). Two primers, the forward primer with internal *Bam* H1 (underlined) site

- 7 -

[5' ATATTGGATCCATATTTGATGCTAGTT TA 3'; nt. 3 - 20] and a reverse primer with *Eco* R1 site, (5' GGCGCGAATTCTTACTC CCCCAAGAAAA 3'; nt. 1230 - 1214) designed based on the previously published sequence (ibid, Vimr, E.R. 1992) were used for PCR using the following conditions: 94 °C, 1 min; 50 °C, 1 min, and 72 °C, 2 min for 35 cycles. Agarose gel analysis of the product showed the presence of one major band with the expected size of about 1.2 kb. The fragment obtained was purified by agarose gel electrophoresis, digested with *Bam* HI and *Eco* RI and subcloned into a similarly digested pRSET vector (Invitrogen Co., San Diego, CA) following standard molecular biological techniques (Sambrook, J. et al. (1989) *Molecular cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.). The ligation mixture was then used for transformation of competent cells of the BL21(DE3) strain of *E.coli* (Novagen, Madison, WI). The clone containing the expression vector was confirmed by sequencing of both strands using an automated DNA sequencer (ABI 377) at the TSRI Core facility.

#### *Expression of the K92 neuS gene.*

Since the DH5 $\alpha$  strain of *E.coli* lacking the *kps* gene cluster does not have sialyltransferase activity (ibid, Steenberg, S.M. 1990), it was used initially to express the gene. This strain has a pilli forming gene in its chromosome and therefore does not require any pressure for the expression of its sex pilli. M13 phage containing the T7 RNA polymerase gene (Invitrogen) was used to infect DH5 $\alpha$ F' transformed with pRSET vector containing the cloned *neuS* gene. The transformed cells were grown in LB medium (with 1 mM MgCl<sub>2</sub>) containing 100 (g carbicillin/ml at 37 °C to O.D.<sub>600</sub> ~0.3 and then 1 mM IPTG was added. After one hour of incubation, the M13/T7 phage was added to infect the cells as described by the supplier (Invitrogen), and harvested after 5 hours of incubation. An enzyme activity assay and SDS-PAGE of the cell lysate (15 K supernatant) showed expression of the *neuS* gene in DH5 $\alpha$ F'. A band migrating as ~ 47.5 kd in the 12% SDS-PAGE appeared within 1 hour of incubation after infection with T7 RNA polymerase gene containing M13 in the presence of IPTG (as judged by Western blot). The relative intensity of the 47.5 kd band increased with time

- 8 -

and reached maximum after 4 hrs. Enzymatic assay of the cell free extract using sialic acid as acceptor also indicated the expression of the K92 polysialyltransferase.

However, the DH5 $\alpha$ F' cells transformed with pRSET vector also yielded a band comigrating with the 47.5 kd band in SDS-PAGE. Attempt to separate these bands using Ni<sup>2+</sup>-NTA agarose proved to be difficult. We therefore decided to express this protein in the HMS174(DE3)Lys or BL21(DE3) strain of *E.coli* (Invitrogen).

The transformed BL21(DE3) cells containing the *neuS* gene from the K92 strain of *E. coli* were grown exponentially in LB medium (with 1 mM MgCl<sub>2</sub>) containing 100 (g carbicillin/ml at 37°C until A<sub>600</sub> ~0.3 was reached. Expression of the *neuS* gene was achieved at 37 °C by induction with IPTG as described in the expression kit (Invitrogen, Carlsbad, CA). The cells were harvested after 5 hours of incubation.

A DNA plasmid designated as BL21/DE3(8,9 PST) containing the *neuS* gene from K92, obtained above, has been deposited with American Type Culture Collection (ATCC) on or before August 10, 1999 and has been assigned the ATCC accession number \_\_\_\_\_. Briefly, the DNA (*neuS*) was originated from *escherichia coli* K92 strain by PCR to clone the  $\alpha$ 2,8/2,9 polysialyltransferase. The DNA was subcloned in pRSET vector (Invitrogen) and the resultant plasmid DNA (8,9 PST) was transformed into *escherichia coli* GL21(DE3). This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable plasmid for 30 years from the date of each deposit. The plasmid will be made available by ATCC under the terms of the Budapest Treaty which assures permanent and unrestricted availability of the progeny of the plasmid to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 U.S.C. §122 and the Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638).

The assignee of the present application has agreed that if the plasmid deposit should die or be lost or destroyed when cultivated under suitable conditions, it will be promptly replaced on notification with a viable specimen of the same plasmid. Availability of the deposit is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

*Western blot:*

This analysis was done by following a standard technique (Harlow, E. et al. (1988) *Antibodies*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.). The protein samples were boiled for 8-10 mins in 1 x Laemmli gel sample buffer either in the absence or presence of 10%  $\beta$ -mercaptoethanol. Electrophoresis was performed using 10% SDS-polyacrylamide gel in Tris/glycine-SDS buffer. After the proteins were transferred to a nitrocellulose membrane, the blot was blocked with a blocking buffer (blotto in TBS and 0.1% Tween-20) and developed by adsorption with the mouse anti-(His)<sub>5</sub> monoclonal antibody (Qiagen, Valencia, CA) diluted (1 : 500) with the blocking buffer. The blot was incubated with horseradish peroxidase-conjugated sheep anti-mouse secondary antibody (1 : 1000; Amersham Corp.). The protein bands were visualized either by chemiluminescence as suggested by the supplier of the reagents (Amersham Corporation) or by staining with the immunoPure Metal Enhanced DAB Substrate Kit (Pierce, Rockford, IL).

*Sialyltransferase assay:*

The assay was carried out essentially as described by Vimr et al (Steenbergen, S. M. et al. (1992) *J. Bacteriol.* 174: 1099-1108) with the following modifications: after harvesting, the cells were washed three times with 25 mM Tris HCl (pH 8.0) and then resuspended in 25 mM Tris HCl (pH 8.0) containing 5 mM MgCl<sub>2</sub>, 5 mM dithiothreitol (DTT), and 1 (l/mL protease inhibitor cocktail (Sigma). Cells were lysed three times by using a French Press (AMINCO; 1,500 psi). The cell debris was removed by centrifugation twice at 15,000 rpm and the supernatant was collected (termed the 15 K

- 10 -

Sup). This supernatant was then centrifuged again at 100,000x g (~ 40 K rpm) using a Beckman ultracentrifuge (Model L5-50). Both the supernatant (termed the 40 K Sup) and the pellet were saved. The pellet was resuspended in a buffer containing 25 mM Tris-HCl, 5 mM MgCl<sub>2</sub>, 5 mM DTT, and 0.1% Triton CF-54. The supernatants and the pellet were stored on ice, and used for assay within 2 h.

Without the addition of acceptor, the endogenous enzyme activity was determined. The exogenous activity was then detected by addition of sialic acid as acceptor and CMP[<sup>14</sup>C]NeuAc as donor in a reaction buffer containing 25 mM Tris-HCl (pH 8.0), 5 mM MgCl<sub>2</sub>, 5 mM DTT, and 0.5% Triton CF-54. Other substrates were also used, including colominic acid. Both the endogenous and exogenous enzyme activity assays measure the transfer of <sup>14</sup>C-labeled NeuAc to the acceptor. Unreacted radiolabeled substrates were separated by DEAE-cellulose TLC ( *n*-propanol/14M NH<sub>4</sub>OH/H<sub>2</sub>O:: 6 : 1: 3) or by Sephadex G-25 column chromatography. Radioactivity remaining at the origin and/or at the top of the TLC plate or the product obtained at the void volume of Sephadex G-25 column, was quantitated by liquid scintillation spectrometry. For analysis using Sephadex G-25 column chromatography, a column (1 cm x 3.5 cm) of Sephadex G-25 (Pharmacia) in water was prepared. The radiolabeled cell-free reaction mixture (60 l) was loaded and washed with 1.5 ml of water, which was collected and counted. In some experiments, the activity was determined by separating the unused CMP[<sup>14</sup>C]NeuAc by Dowex 1X8 (phosphate form) column chromatography (Williams, M. A. et al. (1995) *Glycoconj. J.* 12: 755 – 761). The initial rates were estimated graphically, and activity was expressed as pmoles of sialic acid transferred per hour.

#### *Thin-layer chromatography and fluorography:*

After the cell-free reaction was complete, the proteins were removed by an Amicon filter (MWCO 10 K), and the supernatant containing oligomeric reaction products was separated by Silica gel 60 (aluminum backed) and/or DEAE-cellulose (plastic backed) thin-layer chromatography (TLC) using the following solvent systems:

- 11 -

(a) *n*-propanol, 14 M NH<sub>4</sub>OH, H<sub>2</sub>O :: 6: 1: 3; (b) chloroform : methanol: 0.02% CaCl<sub>2</sub>:: 30 : 55: 15. Control chromatograms were calibrated with mono- to hexasialosyl oligomers (Calbiochem, San Diego, CA) which were detected by orcinol spray, as described by Corfield and Schauer (*Sialic Acids: Chemistry, Metabolism, and Function*. (Schauer, R., ed) *Cell Biology Monograph*, Vol 10, pp. 77-94, Springer-Verlag, New York, 1982). This method resolved monomeric through octameric sialic acids.

Oligomers composed of nine or more sialosyl residues were retained at the origin. Labeled chromatograms were sprayed with En<sup>3</sup>Hance (New England Nuclear) and fluorographed against an intensifier screen. After fluorography, sialosyl oligomers were detected on Silica gel 60 TLC plates by orcinol spray for alignment of radioactive signals with colorimetrically detected bands. For analysis using DEAE-cellulose TLC, the position of the cell-free <sup>14</sup>C-labeled reaction product(s) was marked after alignment of radioactive signals, cut and counted.

#### 15 *Isolation and purification of polysialylated oligosaccharides:*

Strains of *Escherichia coli* transformed with vector only or with the K92 *neuS* gene, were used for the extraction of polysaccharide following the method of Kasper et al (Kasper, D. L. et al. (1973) *J. Immunol.* 110, 262-268) with the following modifications. For K92 polysaccharide, the K92 strain of *E.coli* was grown in 2 L of Davis' supplemental minimal medium (ATCC media formulation # 54) at 37 °C overnight. The K1 strain of *E.coli* transformed with K92 *neuS* gene was grown in 2 L of Davis' supplemental minimal medium containing 2% glycerol instead of glucose. The cells were grown to O.D.<sub>600</sub> ~ 0.3 and 1 mM IPTG (final concentration) was added. After incubation at 37 °C for 1 hr., M13/T7 phages (Invitrogen; 10 pfu/cell) were added and incubated at 37 °C. After overnight growth the organisms were removed by centrifugation (48,000 x g for 30 min at 4 °C), and the supernatant was collected and filtered through a 0.45 μm Millipore filter. Hexadecyltrimethyl ammonium bromide (Cetavlon; 0.3%; Sigma) was added to the supernatant with stirring and the precipitate formed was collected by centrifugation. The precipitate was solubilized in 0.9 M CaCl<sub>2</sub>, and reprecipitated with three volumes of chilled (-20 °C) absolute ethanol. The ethanol

- 12 -

precipitation from 0.9 M CaCl<sub>2</sub> was repeated three times. The final product was dialyzed against water and lyophilized. The final purification was done using a column (2 cm x 25 cm) of Biogel P2 (Pharmacia) eluted with water following usual procedure, and verified by polyacrylamide gel electrophoresis following the method of Troy and McCloskey (ibid 1979). After hydrolysis by sulfuric acid (0.1 N H<sub>2</sub>SO<sub>4</sub>, 80 °C), quantitation of sialic acid was determined by the thiobarbituric acid procedure as described previously (Liu, J. et al. (1992) *J. Am. Chem. Soc.* **114**: 3901-3910).

#### *Protein Assay:*

This was done using bicinonic acid (BCA) reagent following the instructions provided by the supplier (Pierce Chemical Co.).

#### *Mass spectrometry-analysis:*

The electrospray ionization (ES-MS) mass spectrometry experiments were performed on an API III Perkin Elmer SCIEX triple quadrupole mass spectrometer. Electrospray samples were typically introduced to the mass analyzer at a rate of 4.0 ml/minute. The positive and negative ions, generated by charged droplet evaporation, enter the analyzer through an interface plate and a 100 mm orifice, while the declustering potential is maintained between 50 – 200 V to control the collisional energy of the ions entering the mass analyzer. The emitter voltage is typically maintained at 5000 V. The *m/z* was determined for the major peaks.

#### *NMR analysis:*

<sup>13</sup>C Nuclear magnetic resonance spectra were recorded at ca. 23 °C on a Bruker AMX-400 or DRX-600 spectrometer operating in the pulsed Fourier transform mode using broadband proton noise decoupling. The polysaccharides were run as deuterium oxide solutions at pH 7.0. The solvent, D<sub>2</sub>O, served as an internal lock signal. DMSO was often used as internal reference. The <sup>13</sup>C spectrum of polysaccharides from K1 and K92 determined in this study were found to be identical to that presented by Egan et al (ibid, Egan, W. 1977). The K1 polysaccharide NHCO (amide carbonyl) resonance from



the present and Egan's studies were taken to have the same chemical shift and all remaining signals referenced accordingly.

#### Results:

##### 5 Cloning of the *neuS* gene from K92:

Previously, the *neuS* gene from the K1 strain of *E.coli* was cloned and found to have the  $\alpha$ 2,8-polysialyltransferase activity. Using the K1 *neuS* gene as a probe, Vimr et al cloned a 1230 bp gene (ibid, Vimr, E.R. 1992) from the K92 strain of *E.coli* that had 87.3% homology to the K1 gene. The deduced protein sequence from this gene  
10 indicated the same number of amino acids (total 409 aa) with 83% homology to that of K1 at the protein level. Previous structural studies on the polysaccharide antigen of this *E. coli* K92 strain (Bos-12) suggested the presence of polysialic acid with alternating (-2,8 and (-2,9 linkages (ibid, Egan, W. 1977). Therefore, the gene product from the K92 strain is assumed to confer polysialyltransferase activity (14, 23). However,  
15 expression of the *neuS* gene from K92 was not clearly demonstrated, nor was it shown to form a polymer of sialic acid *in vitro* with alternating  $\alpha$ 2,8/2,9-linkages.

To characterize the K92 *neuS* gene product, we have cloned this gene from the *E. coli* K 92 strain using a PCR based approach. The primers were designed based on  
20 the previously published sequence (ibid, Vimr, E.R. 1992), and used to amplify the full-length clone of the *neuS* gene from the genomic DNA of the K92 strain. The 1.23 kb fragment obtained by PCR was subcloned in pRSET (Invitrogen) for expression of the *neuS* gene product as a fusion protein with the hexameric histidine tag fused at its *N*-terminal end (Fig. 1). The clone was verified by double-strand sequencing of the  
25 entire fragment including the restriction sites.

A hydrophilicity plot (Hopp, T. P. et al. (1981) *Proc. Natl. Acad. Sci. U.S.A.* **78**, 3824-3828; and Kyte, J. et al. (1982) *J. Mol. Biol.* **157**, 105-132) revealed two potential membrane-spanning regions in this protein of 409 amino acid residues. The first one is  
30 located 177 residues from the *N*-terminus. It consists of 19 hydrophobic amino acids

- 14 -

bordered by three upstream lysine residues. Interestingly, this first transmembrane domain is bordered on either end by a proline residue. Proline is known to confer conformational constraints of many biologically important proteins, as evidenced by site-directed mutagenesis studies (ibid, Datta, A.K. 1998; for a review, see Vanhoop, G. et al. (1995) *FASEB J.* **9**, 736-744). A similar KKKP motif, found to be present in the ST6Gal I (for nomenclature, see Ref. 12) polypeptide, is part of a proposed signal anchor sequence (Weinstein, J. et al. (1987) *J. Biol. Chem.*, **262**, 17735-17743). The second transmembrane domain is located 327 residues from the *N*-terminus. It consists of 17 hydrophobic amino acid residues bordered by two upstream lysine residues and a proline residue at its C-terminus. Notably, lysine and serine are predominantly present in this domain. The presence of these two transmembrane domains suggests that this protein is membrane-bound as further supported by the Western blot (see below). This feature appears to be unique among the cloned bacterial sialyltransferases, the hydrophilicity plot of which suggests the presence of only one potential membrane-spanning region.

*Expression of the K92 neuS gene:*

For expression, we used pRSET (Invitrogen), a prokaryotic expression vector designed to obtain a hexameric histidine tag fused at the *N*-terminal sequence of the desired protein. Due to the lack of any antibody available against the K92 *neuS* gene product, the polysialyltransferase was expressed as a fusion protein, and detected by the Western blot using anti-(His)<sub>6</sub> antibody (Qiagen Inc., Valencia, CA).

*SDS-Polyacrylamide gel electrophoresis and Western blot:* The cell free crude extract (15 K Sup and 40 K Sup) and the cell pellet, suspended in 25 mM Tris-HCl (pH 8.0) containing 5 mM MgCl<sub>2</sub> and 0.1% Triton CF-54, obtained by ultracentrifugation were analyzed by SDS-PAGE. Coumassie blue staining showed the presence of various bands including a major band at about 47.5 kd, the expected size for the *neuS* gene product. This band was absent in the control (cells transformed with pRSET vector only). Replica gel was used to transfer the proteins to a nitrocellulose membrane and

detected by using mouse monoclonal anti-(His)<sub>5</sub> antibody (Qiagen, Valencia, CA). The blot was finally developed by using Enhanced DAB substrates following the protocol of the supplier (Pierce) or by chemiluminescence technique as described earlier (Datta, A. K. et al. (1998) *J. Biol. Chem.* **273**, 9608-9614). The Western blot clearly showed the presence of a single band at about 47.5 kd (Fig. 3). The  $\alpha$ 2,8/2,9-polysialyltransferase was also found to be present in the 40K supernatant. Our initial attempt to purify the protein using Ni<sup>2+</sup>NTA agarose column failed. Though the fusion protein apparently binds to the Ni<sup>2+</sup>NTA agarose, non-specific binding with other cellular proteins was also observed. Therefore, the 40K Sup was used in this study for enzyme assay and analysis of its product(s).

*Sialyltransferase assay:*

The cell free crude extract (15 K Sup), 40 K supernatant (40 K Sup), and the pellet were used for the assay of various acceptor substrates and CMP [<sup>14</sup>C]NeuAc as donor substrate. The activity could be traced in all these fractions. After the reaction was over, the products were analysed by TLC or by Sephadex G-25 column chromatography. Fig. 4 shows a representative analysis. Using cold sialic acid as acceptor and CMP [<sup>14</sup>C]NeuAc as donor, a major spot was detected on TLC using various solvent systems. Interestingly, this new spot behaved as non-polar material on DEAE-cellulose TLC (Fig. 4C). It was found that sialic acid served as a good acceptor, whereas colominic acid did not (Table I). 9-O-acetyl sialic acid was not well accepted, indicating that the polymerization probably starts at the C9 position of the sialic acid acceptor. Notably, pentameric and hexameric polysialosides with  $\alpha$ 2,8-linkages were not accepted, whereas the corresponding dimer and trimer (Calbiochem) served as poor acceptors. Among the glycolipids tested, GD<sub>3</sub> and GQ<sub>1b</sub> also served as good acceptors. However, other sialyl gangliosides tested were poor substrates (Table I).

*Structural determination of the cell-free reaction product :*

For structural determination, the cell-free reactions were carried out, using the 40K supernatant as the enzyme source, with sialic acid and unlabeled CMP-NeuAc in a

- 16 -

molar ratio of 1:10 to obtain the reaction product(s) in a sufficient quantity. Since it was known that the byproduct CMP inhibits the forward reaction, alkaline phosphatase was added to remove CMP in order to increase the yield. As mentioned above, the product moved as a non-polar material on DEAE-cellulose TLC, a characteristic utilized for purification of the cell-free reaction product(s). After the reaction was complete, the reaction mixture was passed through a column of Dowex 1X8 (phosphate form) to remove unreacted CMP-NeuAc and sialic acid. The negative ion mass spectral analysis (ES-MS.) showed a major peak at  $m/z$  1419 for (M-3H<sub>2</sub>O-H) and at  $m/z$  1401 for (M-4 H<sub>2</sub>O-H). This spectrum was similar to that of the commercially obtained  $\alpha$ 2,8-polysialic acid (pentamer; Calbiochem). While the authentic sample showed a fragmentation pattern accounting for the tetramer- ( $m/z$  at 1182 for M- 3H<sub>2</sub>O-H), trimer- ( $m/z$  at 890 for M-3H<sub>2</sub>O-H), dimer- ( $m/z$  at 599 for M-3H<sub>2</sub>O-H), and monomer- ( $m/z$  at 308 for M-3H<sub>2</sub>O-H) fragments, the fragmentation pattern for the reaction product was slightly different, probably due to the presence of alternating  $\alpha$ 2,8 &  $\alpha$ 2,9-linkages in the cell-free reaction product(s). The degree of polymerization appears to be limited by the concentration of CMP-NeuAc. The production of a pentamer as the major product in the cell-free reaction is probably due to the limitation of CMP-NeuAc concentration along with the limited degree of polymerization. Increasing the amount of CMP-NeuAc in the cell-free reaction indeed increases the chain length of the sialyl polymer as judged by mass-spectrometry. While the MALDI-MS (Core Facility, The Scripps Research Institute) of the commercially available pentamer (Calbiochem) showed a peak for  $m/z$  at 1473, a peak at  $m/z$  1474 was obtained with 10 mM CMP-NeuAc and at  $m/z$  3830 with 20 – 30 mM CMP-NeuAc.

The *E.coli* strain K1 which forms the homopolymer of (-2,8-linked sialic acids in its capsule was transformed with the *neuS* gene from K92. This was done to investigate whether the K92 *neuS* gene product competes with the endogenous  $\alpha$ 2,8-polysialyltransferase for the same endogenous acceptor *in vivo*. The capsular polysaccharide from the transformed K1 was isolated and purified by Biogel P2 column chromatography as mentioned in 'Materials and Methods'. <sup>13</sup>C-NMR of this

- 17 -

polysaccharide in D<sub>2</sub>O showed a spectrum different from that of the K1 and K92 derived polysialic acids. The major peaks for the NCOCH<sub>3</sub> and NCOCH<sub>3</sub> were similar to those of both K1 and K92. However, the signal for C-2 at  $\delta$ 103.44 was comparatively weaker. This may be due to the complex nature of the polysaccharide from transformed cells. Moreover, the <sup>13</sup>C-NMR spectra obtained for the transformed K1 was similar to that of the polymer obtained from the K92 strain of *E.coli*, which also showed two closely adjacent signals at  $\delta$  23.36 and 23.51. It was shown earlier that this particular strain of *E.coli* contains heteropolysialyl oligosaccharide with alternating  $\alpha$ 2,8/2,9-linkages (ibid, Egan W. 1977). This complexity was also evident in the <sup>1</sup>H-NMR spectrum which showed two peaks at  $\delta$ 1.99 and  $\delta$ 1.96. While a detailed structural study is in progress, the preliminary data indicates that the polysaccharide isolated from the transformed K1 has both  $\alpha$ 2,8- and  $\alpha$ 2,9-linkages present in random sequences. This suggests that not only is the K92 *neuS* gene functional in the K1 strain of *E.coli*, but also that its expression disrupted normal polysialyl chain elongation. This result is probably due to the competition for the same endogenous acceptor *in vivo*. This also suggests that the endogenous acceptor is neither sialic acid nor colominic acid, but is common for both the  $\alpha$ 2,8- and  $\alpha$ 2,8/2,9-polysialyltransferases.

Interestingly, the cell-free enzyme reaction product(s) appears to be prone to lactone formation. The radiolabeled product ran as a non-polar sialoside on DEAE-cellulose TLC and also passed through a column of Dowex 1X 8 (phosphate form). Lactone formation appears to depend on sample preparation conditions, and seems to be preferable at lower pH. This lactonization was also observed at pH 8.0, presumably because the pH of the reaction mixture decreased during the reaction. The electrospray mass analysis also suggested lactone formation of in the cell-free reaction product(s). The peak for *m/z* at 1401 is consistent with the loss of four H<sub>2</sub>O to form 4 lactones and the major peak for *m/z* at 1419 is consistent with the formation of 3 lactones from the pentameric product. Additional supporting evidence for the presence of lactones is the <sup>13</sup>C-peaks at ~97ppm which are also observed in the authentic pentamer lactone prepared from the partial hydrolysis of the K92 polysaccharide.

These peaks shift to ~103.5ppm when lactone hydrolysis under basic conditions is performed. Based on the recent observation of regioselective lactonization of (-2,8-linked oligomeric sialic acid (Cheng, M.-C. et al. (1999) *Angew. Chem. Int. Ed. Engl.*, **38**, 686-689; and Zhang, Y. et al. (1999) *J. Biol. Chem.*, **274**, 6183-6189), the carboxyl group of the non-reducing end sialic acid may exist as an open form.

For the mass-spectral analysis of the enzyme reaction product, the cell-free reaction was carried out using 40 K Sup. The reaction mixture contained 1 mM sialic acid and 10 mM CMP-NeuAc as donor in a reaction buffer containing 25 mM Tris-HCl (pH 8.0), 5 mM MgCl<sub>2</sub>, 5 mM DTT, 0.5% Triton CF-54. To drive the forward reaction, the liberated CMP was removed by the addition of alkaline phosphatase (1 U). After the reaction was over, the reaction material was passed through an Amicon filter (10 MWCO) and the filtrate was used for analysis. The cell-free enzyme reaction product behaved similar to the pentameric sialic acid (Calbiochem), on TLC. in various solvent systems. Mass spectra were compared with that of commercially available pentameric sialic acid. Negative ion mass spectrum (ES-MS) of : (A) standard pentameric polysialic acid, and (B) cell-free reaction product. The major peaks for  $m/z$  were marked by arrow and described in the text. The molecular ion ( $M - H^+$ ) was also shown. Some minor products with higher mass ( $m/z$ ) were also observed.

Mass-spectral analysis of the enzyme reaction products was performed with increasing concentration of CMP-NeuAc. The cell-free enzyme reactions were performed as above with 1 mM sialic acid and increasing concentration of CMP-NeuAc ( 10 mM, 15 mM, 20 mM, and 30 mM). After the reaction was complete, the materials were filtered (Amicon; 10 MWCO) and the filtrate from each reaction tube was directly used for mass-spectrometry (MALDI-MS). The spectra were: A, standard pentamer (Calbiochem), B, reaction product using 10 mM CMP-NeuAc and C, reaction product using 20 mM CMP-NeuAc. The major peaks for  $m/z$  were shown by arrow and described in the text. A similar spectrum (as C) was observed using 30 mM CMP-NeuAc.

- 19 -

<sup>13</sup>C-NMR analysis was performed on the capsular polysaccharide. The spectra were recorded on a Bruker DRX-600 spectrometer. The scale is in parts per million and relative to external DMSO. The spectra of the purified capsular polysaccharides were from K1 (A), K1 transformed with K92*neuS* (B), and K92 (C). The numbering of the carbon atoms is based on the previously published results (ibid, Egan, W. 1977).

<sup>1</sup>H -NMR analysis was performed on the capsular polysaccharide of K1 transformed with K92/*neuS* gene. The spectra were recorded on a Bruker DRX-600 at an ambient temperature. Only the region for amide methyl groups from  $\alpha$ 2,8- and  $\alpha$ 2,9-linkages of the purified capsular polysaccharide have been shown for comparison. The isolation and purification of the capsular polysaccharides were mentioned in the *Materials and Methods*. The spectra of the capsular polysaccharides were from K1 (A), K92 (B), and K1 transformed with K92/*neuS* (C). While the K1 sample showed only a singlet at  $\delta$ 1.99, K92 showed two peaks at  $\delta$ 2.00 and  $\delta$ 1.96. The spectrum obtained from the transformed K1 was broad and complex, especially at  $\sim$  $\delta$ 1.99.

<sup>13</sup>C-NMR analysis of the enzyme reaction product was performed. After the enzyme reaction, the protein was removed by filtration (Amicon; 10K). The enzyme reaction product was separated from unreacted sialic acid and CMP-NeuAc by passing through a column of Dowex 1X8 (PO<sub>4</sub>- form) eluting with phosphate buffer. The product was collected in the void volume and desalted by passing through a small column of Sephadex G-50 eluting with water. The desired material was collected in the void volume, freeze-dried, and dissolved in D<sub>2</sub>O for NMR analysis. The spectra were recorded on a Bruker DRX-600 spectrometer at an ambient temperature (20 °C). The scale is in parts per million and relative to external DMSO. Spectrum A, commercially available (-2,8-linked pentameric sialic acid used as standard, results from approximately 25K accumulations. Spectrum B, partially purified cell-free reaction product, results from approximately 40K accumulations.

**Findings:**

While sialic acid is ubiquitous in eukaryotes, particularly in mammals (ibid, Tsuji, S. 1996), it is not detected in prokaryotes other than some pathogenic bacteria. These include some *Escherichia coli* strains, some *Neisseria meningitidis* strains and bacteria of the O serotype including Salmonella (ibid, Barry, G.T. 1962 and 1965). Though the presence of polysialyltransferase activity in *E.coli* was reported earlier by Roseman et al (ibid, Kundig, F.D. 1971), the nature of the gene and its product was not clearly demonstrated until recently. The cloned *neuS* gene from K1 showed that its product has similar size but no sequence homology to any of the mammalian sialyltransferases. Expression of the K1 *neuS* gene indicates that this 47 kd protein synthesizes polysialic acid *in vitro* (ibid, Weisgerber, C. 1991). A similar gene was cloned from the K92 strain of *E.coli*, the capsule of which was shown to contain heteropolysialic acid (-8NeuAc $\alpha$ 2,9NeuAc $\alpha$ 2-) (ibid, Egan, W. 1977). This gene product differs by 70 amino acids when compared with that of the *neuS* gene product of the K1 strain (ibid, Vimr, E.R. 1992). Of the observed amino acid replacements, 36 were conservative. On the basis of such homology, it was postulated that the K92 gene evolved from *neuS* of K1 (ibid, Vimr, E.R. 1992). By complementation assay, the K92 *neuS* gene was shown by this group (ibid, Steenbergen, S.M. 1992) to express polysialyltransferase activity yielding a product that was recognized by men C antiserum *in vivo*, suggesting that this gene might produce sialoside with alternating  $\alpha$ 2,8/2,9-polysialyl linkages. However, because men C antiserum interacts with both homopolysialic acid (-9-NeuAc $\alpha$ 2-) from *Neisseria meningitidis* Group C and heteropolysialic acid (-8NeuAc $\alpha$ 2,9NeuAc $\alpha$ 2-) from the K92 strain of *E.coli* (Barry, G. T. (1965) *Bull. Soc. Chim. Biol.* **47**, 529-533.34), structural identification of the cell-free reaction product(s) was warranted. Previously, the expression of the K92 *neuS* gene was not clearly demonstrated, nor was it shown that this gene product catalyzes the synthesis of heteropolysialic acid (-8NeuAc $\alpha$ 2,9NeuAc $\alpha$ 2-) *in vitro*.

The polysialyltransferase (polyST) encoded by *neuS* in *E.coli* uses CMP-sialic acid as a donor and catalyzes sequential sialylation at the nonreducing end of



- 21 -

appropriate acceptors. Using K1 *neuS*, the polymerase activity was detected *in vitro* with sialyloligomers (designated colominic acid) or with certain gangliosides, such as GD<sub>3</sub> (Weisgerber, C. 1991) as substrates. However, it was shown previously that this gene product could not initiate *de novo* polysialic acid synthesis (ibid, Steenbergen, S.M. 1992), indicating a requirement for an as yet undefined *in vivo* primer. This primer, or polymerization initiator, does not appear to be colominic acid, since this polymer was neither elongated efficiently *in vitro* (18) nor the elongated product detected *in vivo* (Barry, G. T., et al., (1962) *J. Gen. Microbiol.* **29**, 335-352). Using K92 *neuS*, we have found that colominic acid is not an acceptor. In fact, among the acceptors tested, only sialic acid and certain gangliosides proved to be good acceptors.

In conclusion, it is disclosed herein that the *neuS* gene product from *E.coli* K92 exhibits  $\alpha 2,8/2,9$ -polysialyltransferase activity both *in vitro* and *in vivo*. Apparently a single polypeptide (as judged by the Western blot) for this polysialyltransferase catalyzes the synthesis of polysialic acid by sequentially transferring sialic acids with alternating  $\alpha 2,9$ - and  $\alpha 2,8$ - linkages. Previously, bacterial KDO-transferase was shown to possess such dual linkage specificity (Glode, M.P., et al., (1977) *J. Infect. Diseases*, **135**, 94-102). Thus, enzymes capable of forming multiple different linkages may not be uncommon in nature. Though the membrane-bound K92 *neuS* enzyme accepted exogenous neuraminic acid as the best substrate in this study, it may prefer other sialic acid-containing glycolipids or glycoproteins. Work is in progress to define the substrate specificity of this enzyme and to determine the detailed structures of the enzyme products.

**Table I: Substrate specificity of *neuS* gene product of *E.coli* K92 expressed in BL21(DE3):**

The reaction mixture (60 l) contained 1 M each of the following acceptors and 9 nmol of CMP[<sup>14</sup>C]NeuAc (specific activity: 8000 cpm/nmol) as donor substrate. The reactions were carried out at 37 °C for 1 hr using 20 (g of 40K Sup as mentioned in 'Materials and Methods.' The reaction mixture (1 l) was spotted on a plastic backed DEAE-cellulose TLC plate, and ran in *n*-propanol:14.5M NH<sub>4</sub>OH:water :: 6:1:3. After air-drying, the plate was exposed to Kodak's XAR-5 film for overnight at -70° C. The area corresponding to the reaction product was marked, cut and then counted in scintillation fluid.

Potential acceptor substrates tested	cpm obtained (per 60 ul reaction)	Total sialic acid trans- ferred (pmol)
Sialic acid (5AcNeuAc)		
Monomer	3780	470
Dimer	1080	140
Trimer	1560	140
Pentamer	0	0
Hexamer	0	0
9-O-acetyl sialic acid	900	110
Colominic acid	0	0
GD <sub>3</sub>	2880	360
GM <sub>3</sub>	1440	180
GD <sub>2</sub>	900	110
GT <sub>1a</sub>	460	40
GT <sub>1b</sub>	1140	130
GQ <sub>1b</sub>	2460	310
Ganglioside mixtures	720	90

- 23 -

What is claimed is:

1. DNA plasmid (ATCC \_\_\_\_\_) designated as BL21/DE3(8,9 PST) containing the neuS gene from *escherichia coli* K92 and encoding  $\alpha 2,8/2,9$  polysialyltransferase from *escherichia coli* K92.
2. A transformed cell having a gene encoding  $\alpha 2,8/2,9$  polysialyltransferase from *escherichia coli* K92.
3. A process for obtaining purified  $\alpha 2,8/2,9$  polysialyltransferase comprising the following steps:  
  
Step A: expressing a gene encoding  $\alpha 2,8/2,9$  polysialyltransferase within a transformed cell having said gene for producing said  $\alpha 2,8/2,9$  polysialyltransferase; and then  
  
Step B: isolating the  $\alpha 2,8/2,9$  polysialyltransferase expressed in said Step A.
4. A process according to claim 3 wherein the  $\alpha 2,8/2,9$  polysialyltransferase is from *escherichia coli* K92.
5. Purified recombinant  $\alpha 2,8/2,9$  polysialyltransferase.
6. Purified recombinant  $\alpha 2,8/2,9$  polysialyltransferase according to claim 5 wherein the  $\alpha 2,8/2,9$  polysialyltransferase is from *escherichia coli* K92.
7. A method for converting a substrate of  $\alpha 2,8/2,9$  polysialyltransferase into a product, said method comprising the step of contacting the substrate with  $\alpha 2,8/2,9$  polysialyltransferase under conditions for promoting enzymic catalysis of a conversion

- 24 -

of the substrate into the product.

8. A method according to claim 7 wherein the  $\alpha$ 2,8/2,9 polysialyltransferase is from *escherichia coli* K92.




FIG. 1





FIG. 2A



Key:

- [ ] First transmembrane domain (177-195)
- [ ] Second transmembrane domain (327-343)
- [ ] Hexameric histidine

FIG. 2B




FIG. 3

FIG. 4A




FIG. 4B





FIG. 4C










FIG. 4



**I**  
 $C_{55}H_{87}N_5O_{41}$   
 Exact Mass: 1473.49



**II**  
 $C_{55}H_{81}N_5O_{38}$   
 Exact Mass: 1419.46

**FIG. 5**

PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY

I HEREBY DECLARE THAT:

My residence, post office address, and citizenship are as stated next to my name in PART A of page 2 hereof.

I believe I am the original, first, and sole inventor (if only one name is listed) or an original, first, and joint inventor (if plural names are listed) of the subject matter which is claimed and for which a patent is sought on the invention entitled α2,8/2,9 POLYSIALYLTRANSFERASE

the specification of which:

\_\_\_\_\_ is attached hereto

X was filed on August 10, 1999 ✓ as Application Serial No. PCT/US99/18154 ✓  
and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability of this application in accordance with Title 37, Code of Federal Regulations, Sec. 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Sec. 119 of any foreign application(s) for patent or inventor's certificate listed in PART B on page 2 hereof and have also identified in PART B on page 2 hereof any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

I hereby claim the benefit under Title 35, United States Code, Sec. 120 of any United States application(s) listed in PART C on page 2 hereof and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Sec. 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Sec. 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following as my attorneys or agents with full power of substitution to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

Douglas A. Bingham	Reg. No. <u>32,457</u>	Emily Holmes	Reg. No. <u>40,652</u>
Thomas Fitting <sup>5</sup>	Reg. No. <u>34,163</u>	Thomas E. Northrup	Reg. No. <u>33,268</u>
Donald G. Lewis	Reg. No. <u>28,636</u>		

whose mailing address for this application is:

THE SCRIPPS RESEARCH INSTITUTE  
10550 North Torrey Pines Road, Mail Drop TPC-8  
La Jolla, California 92037

See Page 2 attached, signed, and made a part hereof.

PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY

PART A: Inventor Information And Signature

Full name of SOLE or FIRST inventor Chi-Huey Wong  
 Citizenship USA Post Office Address P.O. Box 8154  
Rancho Santa Fe, California 92067

Residence (if different) CA

Inventor's Signature: *Chi-Huey Wong* Date: 3/29

Full name of SECOND joint inventor, if any Gwo-Jenn Shen  
 Citizenship USA Post Office Address 8207 Fosca Street  
Carlsbad, California 92009

Residence (if different) \_\_\_\_\_

Second Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of THIRD joint inventor, if any Arun K. Datta  
 Citizenship India Post Office Address 11286 Carmel Creek Road  
San Diego, California 92130

Residence (if different) \_\_\_\_\_

Third Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of FOURTH joint inventor, if any \_\_\_\_\_  
 Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_

Residence (if different) \_\_\_\_\_

Fourth Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of FIFTH joint inventor, if any \_\_\_\_\_  
 Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_

Residence (if different) \_\_\_\_\_

Fifth Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of SIXTH joint inventor, if any \_\_\_\_\_  
 Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_

Residence (if different) \_\_\_\_\_

Sixth Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

PART B: Prior Foreign Application(s)

Serial No.	Country	Day/Month/Year Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No

PART C: Claim For Benefit of Filing Date of Earlier U.S. Application(s)

Serial No.	Filing Date	Status:
60/096,003	August 10, 1998	<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input checked="" type="checkbox"/> Abandoned <input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned <input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned

See Page 1 to which this is attached and from which this Page 2 continues.

PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY

I HEREBY DECLARE THAT:

My residence, post office address, and citizenship are as stated next to my name in PART A of page 2 hereof.

I believe I am the original, first, and sole inventor (if only one name is listed) or an original, first, and joint inventor (if plural names are listed) of the subject matter which is claimed and for which a patent is sought on the invention entitled α2,8/2,9 POLYSIALYLTRANSFERASE  
the specification of which:

\_\_\_\_\_ is attached hereto  
X was filed on August 10, 1999 as Application Serial No. PCT/US99/18154  
and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability of this application in accordance with Title 37, Code of Federal Regulations, Sec. 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Sec. 119 of any foreign application(s) for patent or inventor's certificate listed in PART B on page 2 hereof and have also identified in PART B on page 2 hereof any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

I hereby claim the benefit under Title 35, United States Code, Sec. 120 of any United States application(s) listed in PART C on page 2 hereof and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Sec. 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Sec. 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following as my attorneys or agents with full power of substitution to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

Douglas A. Bingham	<u>Reg. No. 32,457</u>	Emily Holmes	<u>Reg. No. 40,652</u>
Thomas Fitting	<u>Reg. No. 34,163</u>	Thomas E. Northrup	<u>Reg. No. 33,268</u>
Donald G. Lewis	<u>Reg. No. 28,636</u>		

whose mailing address for this application is:

THE SCRIPPS RESEARCH INSTITUTE  
10550 North Torrey Pines Road, Mail Drop TPC-8  
La Jolla, California 92037

See Page 2 attached, signed, and made a part hereof.

PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY

PART A: Inventor Information And Signature

Full name of SOLE or FIRST inventor Chi-Huey Wong  
Citizenship USA Post Office Address P.O. Box 8154  
Rancho Santa Fe, California 92067  
Residence (if different) \_\_\_\_\_

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of SECOND joint inventor, if any Gwo-Jenn Shen  
Citizenship USA Post Office Address 58207 Fosca Street  
Carlsbad, California 92009  
Residence (if different) CA

Second Inventor's Signature: [Signature] Date: 6-12-01

Full name of THIRD joint inventor, if any Arun K. Datta  
Citizenship India Post Office Address 11286 Carmel Creek Road  
San Diego, California 92130  
Residence (if different) \_\_\_\_\_

Third Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of FOURTH joint inventor, if any \_\_\_\_\_  
Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_  
Residence (if different) \_\_\_\_\_

Fourth Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of FIFTH joint inventor, if any \_\_\_\_\_  
Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_  
Residence (if different) \_\_\_\_\_

Fifth Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of SIXTH joint inventor, if any \_\_\_\_\_  
Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_  
Residence (if different) \_\_\_\_\_

Sixth Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

PART B: Prior Foreign Application(s)

Serial No.	Country	Day/Month/Year Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No

PART C: Claim For Benefit of Filing Date of Earlier U.S. Application(s)

Serial No.	Filing Date	Status:
60/096,003 ✓	August 10, 1998 ✓	<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input checked="" type="checkbox"/> Abandoned
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned

See Page 1 to which this is attached and from which this Page 2 continues.

PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY

I HEREBY DECLARE THAT:

My residence, post office address, and citizenship are as stated next to my name in PART A of page 2 hereof.

I believe I am the original, first, and sole inventor (if only one name is listed) or an original, first, and joint inventor (if plural names are listed) of the subject matter which is claimed and for which a patent is sought on the invention entitled α2,8/2,9 POLYSIALYLTRANSFERASE

the specification of which:

         is attached hereto

  X   was filed on August 10, 1999 as Application Serial No. PCT/US99/18154  
and was amended on                                  (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability of this application in accordance with Title 37, Code of Federal Regulations, Sec. 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Sec. 119 of any foreign application(s) for patent or inventor's certificate listed in PART B on page 2 hereof and have also identified in PART B on page 2 hereof any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

I hereby claim the benefit under Title 35, United States Code, Sec. 120 of any United States application(s) listed in PART C on page 2 hereof and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Sec. 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Sec. 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following as my attorneys or agents with full power of substitution to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

Douglas A. Bingham    Reg. No. 32,457

Emily Holmes

Reg. No. 40,652

Thomas Fitting    Reg. No. 34,163

Thomas E. Northrup

Reg. No. 33,268

Donald G. Lewis    Reg. No. 28,636

whose mailing address for this application is:

THE SCRIPPS RESEARCH INSTITUTE  
10550 North Torrey Pines Road, Mail Drop TPC-8  
La Jolla, California 92037

See Page 2 attached, signed, and made a part hereof.

PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY

ART A: Inventor Information And Signature


Full name of SOLE or FIRST inventor Chi-Huey Wong  
Citizenship USA Post Office Address P.O. Box 8154  
Rancho Santa Fe, California 92067  
Residence (if different) \_\_\_\_\_

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of SECOND joint inventor, if any Gwo-Jenn Shen  
Citizenship USA Post Office Address 8207 Fosca Street  
Carlsbad, California 92009  
Residence (if different) \_\_\_\_\_

Second Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

3-00  
Full name of THIRD joint inventor, if any Arun K. Datta  
Citizenship India Post Office Address 11286 Carmel Creek Road  
San Diego, California 92130  
Residence (if different) \_\_\_\_\_

Third Inventor's Signature:  Date: \_\_\_\_\_

Full name of FOURTH joint inventor, if any \_\_\_\_\_  
Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_  
Residence (if different) \_\_\_\_\_

Fourth Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of FIFTH joint inventor, if any \_\_\_\_\_  
Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_  
Residence (if different) \_\_\_\_\_

Fifth Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of SIXTH joint inventor, if any \_\_\_\_\_  
Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_  
Residence (if different) \_\_\_\_\_

Sixth Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

PART B: Prior Foreign Application(s)

Serial No.	Country	Day/Month/Year Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No

PART C: Claim For Benefit of Filing Date of Earlier U.S. Application(s)

Serial No.	Filing Date	Status:
60/096,003	August 10, 1998	<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input checked="" type="checkbox"/> Abandoned
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned

See Page 1 to which this is attached and from which this Page 2 continues.